keyword
MENU ▼
Read by QxMD icon Read
search

PSMA-617

keyword
https://www.readbyqxmd.com/read/29776913/-177-lu-psma-617-has-activity-in-castration-resistant-prostate-cancer
#1
(no author information available yet)
Radionuclide treatment with [177 Lu]-PSMA-617 (LuPSMA) reduced PSA levels by ≥50% in 57% of patients.
May 18, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29752181/-177-lu-psma-617-for-targeted-prostate-cancer-treatment-a-magic-bullet
#2
Giovanni Paganelli, Ugo De Giorgi
No abstract text is available yet for this article.
May 7, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29752180/-177-lu-psma-617-radionuclide-treatment-in-patients-with-metastatic-castration-resistant-prostate-cancer-lupsma-trial-a-single-centre-single-arm-phase-2-study
#3
Michael S Hofman, John Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott G Williams, Shahneen Sandhu
BACKGROUND: Progressive metastatic castration-resistant prostate cancer is a highly lethal disorder and new effective therapeutic agents that improve patient outcomes are urgently needed. Lutetium-177 [177 Lu]-PSMA-617, a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA) enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer. We aimed to investigate the safety, efficacy, and effect on quality of life of [177 Lu]-PSMA-617 in men with metastatic castration-resistant prostate cancer who progressed after standard treatments...
May 7, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29734118/multidose-formulation-of-ready-to-use-177-lu-psma-617-in-a-centralized-radiopharmacy-set-up
#4
Sudipta Chakraborty, K V Vimalnath, Rubel Chakravarty, H D Sarma, Ashutosh Dash
Lutetium-177-labeled PSMA inhibitor has emerged as a promising modality for targeted therapy of prostate carcinoma. A protocol for regular multidose formulation of ready-to-use 177 Lu-PSMA-617 has been developed based on detailed and systematic radiochemical investigations. The formulation meets the requirements of clinical use and can be shipped to nuclear medicine centres for administration up to 4 days from the date of formulation. The reported protocol would be useful toward facilitating widespread clinical utilization of 177 Lu-PSMA-617 in the management of prostate cancer...
April 26, 2018: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/29732998/an-overview-of-targeted-alpha-therapy-with-225actinium-and-213bismuth
#5
Alfred Morgenstern, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki, Frank Bruchertseifer
Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA-617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy. This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.
May 1, 2018: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29719480/nuclear-medicine-in-prostate-cancer-a-new-era-for-radiotracers
#6
REVIEW
Vincenzo Cuccurullo, Giuseppe Danilo Di Stasio, Luigi Mansi
Natural history of prostate cancer (PCa) is extremely variable, as it ranges from indolent and slow growing tumors to highly aggressive histotypes. Genetic background and environmental factors co-operate to the genesis and clinical manifestation of the tumor and include among the others race, family, specific gene variants (i.e., BRCA1 and BRCA2 mutations), acute and chronic inflammation, infections, diet and drugs. In this scenario, remaining actual the clinical interest of bone scan (BS) in detecting skeletal metastases, an important role in diagnostic imaging may be also carried out by, positron emission tomography/computed tomography (PET/CT) and PET/magnetic resonance imaging (PET/MRI), which combine morphological information provided by CT and MRI with functional and metabolic data provided by PET acquisitions...
April 2018: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29717333/-68-ga-psma-617-pet-ct-a-promising-new-technique-for-predicting-risk-stratification-and-metastatic-risk-of-prostate-cancer-patients
#7
Chen Liu, Teli Liu, Ning Zhang, Yiqiang Liu, Nan Li, Peng Du, Yong Yang, Ming Liu, Kan Gong, Xing Yang, Hua Zhu, Kun Yan, Zhi Yang
PURPOSE: The purpose of this study was to investigate the performance of 68 Ga-PSMA-617 PET/CT in predicting risk stratification and metastatic risk of prostate cancer. METHODS: Fifty newly diagnosed patients with prostate cancer as confirmed by needle biopsy were continuously included, 40 in a train set and ten in a test set. 68 Ga-PSMA-617 PET/CT and clinical data of all patients were retrospectively analyzed. Semi-quantitative analysis of PET images provided maximum standardized uptake (SUVmax) of primary prostate cancer and volumetric parameters including intraprostatic PSMA-derived tumor volume (iPSMA-TV) and intraprostatic total lesion PSMA (iTL-PSMA)...
May 2, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29688951/prediction-of-normal-organ-absorbed-doses-for-177lu-lu-psma-617-using-44sc-sc-psma-617-pharmacokinetics-in-patients-with-metastatic-castration-resistant-prostate-carcinoma
#8
Ambreen Khawar, Elisabeth Eppard, Jean Phlippe Sinnes, Frank Roesch, Hojjat Ahmadzadehfar, Stefan Kürpig, Michael Meisenheimer, Florian C Gaertner, Markus Essler, Ralph A Bundschuh
In vivo pharmacokinetic analysis of [Sc]Sc-PSMA-617 was used to determine the normal organ-absorbed doses that may result from therapeutic activity of [Lu]Lu-PSMA-617 and to predict the maximum permissible activity of [Lu]Lu-PSMA-617 for patients with metastatic castration-resistant prostate carcinoma. METHODS: Pharmacokinetics of [Sc]Sc-PSMA-617 was evaluated in 5 patients with metastatic castration-resistant prostate carcinoma using dynamic PET/CT, followed by 3 static PET/CT acquisitions and blood sample collection over 19...
April 23, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29684274/preclinical-development-of-novel-psma-targeting-radioligands-modulation-of-albumin-binding-properties-to-improve-prostate-cancer-therapy
#9
Christoph A Umbricht, Martina Benešová, Roger Schibli, Cristina Müller
The treatment of metastatic castration-resistant prostate cancer (mCRPC) remains challenging with current treatment options. The development of more effective therapies is, therefore, urgently needed. Targeted radionuclide therapy with prostate-specific membrane antigen (PSMA)-targeting ligands has revealed promising clinical results. In an effort to optimize this concept, it was the aim of this study to design and investigate PSMA ligands comprising different types of albumin binders. PSMA-ALB-53 and PSMA-ALB-56 were designed by combining the glutamate-urea-based PSMA-binding entity, a DOTA chelator and an albumin binder based on the 4-( p-iodophenyl)-moiety or p-(tolyl)-moiety...
May 2, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29651569/external-radiation-exposure-excretion-and-effective-half-life-in-177-lu-psma-targeted-therapies
#10
J Kurth, B J Krause, S M Schwarzenböck, L Stegger, M Schäfers, K Rahbar
BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted therapy with 177 Lu-PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC). To optimize the therapy procedure, it is necessary to determine relevant parameters to define radiation protection and safety necessities. Therefore, this study aimed at estimating the ambient radiation exposure received by the patient. Moreover, the excreted activity was quantified. RESULTS: In total, 50 patients with mCRPC and treated with 177 Lu-PSMA-617 (mean administered activity 6...
April 12, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29623376/trifunctional-psma-targeting-constructs-for-prostate-cancer-with-unprecedented-localization-to-lncap-tumors
#11
James Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala, Anastasia Nikolopoulou, Clarence Williams, David Schlyer, Yize Zhao, Dohyun Kim, John W Babich
PURPOSE: Treatment of late-stage prostate cancer by targeted radiotherapeutics such as131 I-MIP-1095 and177 Lu-PSMA-617 has shown encouraging early results. Lu-177 is preferred to I-131 in clinical settings, but targeted radioligand therapy (RLT) with177 Lu-PSMA-617 has not reached its full potential due to insufficient dose delivery to the tumor. We recently developed a dual-targeting radioiodinated ligand, RPS-027, that targets PSMA and uses albumin binding to enable good tumor uptake and significantly reduced kidney uptake in a preclinical model...
April 6, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29590677/successful-handling-of-an-accidental-extravasation-of-177lu-psma-617-in-the-treatment-of-advanced-prostate-cancer
#12
Michael Jüptner, Maaz Zuhayra, Isong Assam, Ulf Lützen
No abstract text is available yet for this article.
April 2018: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/29578871/prostate-specific-membrane-antigen-expression-in-adrenocortical-carcinoma-on-68ga-prostate-specific-membrane-antigen-pet-ct
#13
Saurabh Arora, Nishikant Avinash Damle, Sameer Aggarwal, Averilicia Passah, Abhishek Behera, Geetanjali Arora, Chandrasekhar Bal, Madhavi Tripathi
We present here a case of metastatic adrenocortical carcinoma with bilateral lung nodules. The patient had been treated with mitotane therapy initially and then was later referred for chemotherapy. There was progression of disease noted on the F-FDG PET/CT. Ga prostate-specific membrane antigen (PSMA) PET/CT was planned to explore the possibility of future treatment with Lu-DKFZ-PSMA-617. It revealed peripheral increased uptake of Ga-HBED-CC-PSMA equal to liver uptake.
March 24, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29536496/relevant-tumor-sink-effect-in-prostate-cancer-patients-receiving-177lu-psma-617-radioligand-therapy
#14
Christian Filss, Alexander Heinzel, Berthold Miiller, Andreas T J Vogg, Karl-Josef Langen, Felix M Mottaghy
AIM: In metastatic prostate cancer patients PSMA targeting radioligands have gained significant impact as theranostic probes. In this study a correlation between total tumor volume (TTV) and measured kidney dose as well as salivary glands (SG) uptake in 177 Lu-PSMA-617 therapy was evaluated. METHODS: Eleven consecutive prostate cancer patients receiving a first cylcle of 177 Lu-PSMA-617 (administered activity of approximately 6GBq) were included. The 68 Ga-PSMA-11 PET/CT scan previous to therapy was used to determine TTV and SG uptake (glandulae submandibularis) employing PMOD version 3...
February 2018: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/29521482/current-application-and-future-perspectives-of-psma-pet-imaging-in-prostate-cancer
#15
Francesco Ceci, Paolo Castellucci, Stefano Fanti
As precision medicine evolves, the contribution of molecular imaging to the management of prostate cancer (PCa) patients, especially for Positron Emission Tomography (PET) imaging, is gaining importance. Highly successful approaches to measure the expression of the prostate specific membrane antigen (PSMA) have been introduced recently. PSMA, the glutamate carboxypeptidase II (GCP-II), is a membrane bound metallo-peptidase that is overexpressed in 90-100% of PCa cells. Due to its selective over-expression, PSMA is a reliable tissue marker for prostate cancer and is considered an ideal target for tumor specific imaging and therapy...
March 8, 2018: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29485430/-44sc-sc-psma-617-biodistribution-and-dosimetry-in-patients-with-metastatic-castration-resistant-prostate-carcinoma
#16
Ambreen Khawar, Elisabeth Eppard, Jean Phlippe Sinnes, Frank Roesch, Hojjat Ahmadzadehfar, Stefan Kürpig, Michael Meisenheimer, Florian C Gaertner, Markus Essler, Ralph A Bundschuh
AIM: [Sc]Sc-PSMA-617 with 3.9-hour half-life, in vitro and in vivo characteristics similar to [Lu]Lu-PSMA-617 and possibility of delayed imaging after 24 hours or later, implies it to be advantageous than [ Ga]Ga-PSMA-617 for pretherapeutic dosimetric assessment for [Lu]Lu-PSMA-617 in metastatic castration-resistant prostate carcinoma (mCRPC) patients. In this study, we investigated biodistribution and radiation exposure to normal organs with [Sc]Sc-PSMA-617 in mCRPC patients. METHODS: Five mCRPC patients (mean age, 69 years) enrolled for [Lu]Lu-PSMA-617 therapy were injected with 40-62 MBq [Sc]Sc-PSMA-617 intravenously; Siemens Biograph 2 PET/CT system was used to acquire dynamic PET data (30 minutes) in list mode over the abdomen, followed by the collection of static PET/CT images (skull to mid-thigh) at 45 minutes, 2 and approximately 20 hours postinjection...
May 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29401146/177lu-prostate-specific-membrane-antigen-super-scan-and-good-response-even-after-1-cycle-of-radioligand-therapy
#17
Kamran Aryana, Soroush Zarehparvar Moghadam, Roham Salek, Ghasemali Divband
A 76-year-old man with castration-resistant prostate cancer and widespread skeletal metastases underwent 2 cycles of Lu-prostate-specific membrane antigen (PSMA) 617 therapy in our department. Whole-body Lu-PSMA scan after the first cycle showed diffuse skeletal PSMA-avid lesions, whereas no PSMA uptake was evident in the kidneys with minimal PSMA uptake by salivary glands (super scan). After 6 weeks, he received the second dose of Lu-PSMA and whole-body scan after the treatment showed remarkable resolution of skeletal metastases and normal PSMA uptake by the kidneys and salivary glands...
April 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29400475/albumin-binding-psma-ligands-optimization-of-the-tissue-distribution-profile
#18
Martina Benešová, Christoph A Umbricht, Roger Schibli, Cristina Müller
The prostate-specific membrane antigen (PSMA) has emerged as an attractive prostate cancer associated target for radiotheragnostic application using PSMA-specific radioligands. The aim of this study was to design new PSMA ligands modified with an albumin-binding moiety in order to optimize their tissue distribution profile. The compounds were prepared by conjugation of a urea-based PSMA-binding entity, a DOTA chelator, and 4-( p-iodophenyl)butyric acid using multistep solid phase synthesis. The three ligands (PSMA-ALB-02, PSMA-ALB-05, and PSMA-ALB-07) were designed with varying linker entities...
March 5, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29326358/targeted-alpha-therapy-of-mcrpc-with-225-actinium-psma-617-swimmer-plot-analysis-suggests-efficacy-regarding-duration-of-tumor-control
#19
Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Markus Hohenfellner, Frederik L Giesel, Uwe Haberkorn, Alfred Morgenstern
The aim of this evaluation is to identify first indicators regarding the efficacy of 225 Ac-PSMA-617 therapy in a retrospectively analyzed group of patients. Methods: Forty patients with metastatic castration-resistant prostate cancer were selected for treatment with 3 cycles of 100 kBq/kgBW 225 Ac-PSMA-617 in 2 months intervals. Prostate-specific antigen (PSA) and blood cell count were measured every 4 weeks. Prostate-specific membrane antigen (PSMA)-PET/CT or PSMA-SPECT/CT were used for baseline staging and imaging follow-up at month six...
January 11, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29247284/third-line-treatment-and-177-lu-psma-radioligand-therapy-of-metastatic-castration-resistant-prostate-cancer-a-systematic-review
#20
REVIEW
Finn Edler von Eyben, Giandomenico Roviello, Timo Kiljunen, Christian Uprimny, Irene Virgolini, Kalevi Kairemo, Timo Joensuu
AIMS: There is a controversy as to the relative efficacy of177 Lu prostate specific membrane antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The aim of our systematic review was to elucidate whether177 Lu-PSMA RLT and third-line treatment have similar effects and adverse effects (PROSPERO ID CRD42017067743). METHODS: The review followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines...
March 2018: European Journal of Nuclear Medicine and Molecular Imaging
keyword
keyword
119470
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"